You just read:

Neurotrope Bioscience Concludes Patient Dosing and Monitoring in its 148 Patient Phase 2 Clinical Trial of Moderate to Severe Alzheimer's Dementia

News provided by

Neurotrope, Inc.

Feb 28, 2017, 08:30 ET